Literature DB >> 18930517

Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease.

Jun Abe1, Ryota Ebata, Toshiaki Jibiki, Kumi Yasukawa, Hirohisa Saito, Masaru Terai.   

Abstract

BACKGROUND: Kawasaki disease (KD) is an acute vasculitis in young children, frequently associated with coronary artery aneurysms. The intravenous infusion of high-dose IgG (IVIG) effectively reduces the systemic inflammation and the incidence of coronary artery lesions, although the precise underlying mechanisms are unknown.
OBJECTIVE: We performed expression profiling of whole blood cells to investigate the mechanisms underlying the effect of IVIG and to identify biomarkers associated with unresponsiveness to IVIG.
METHODS: We compared the transcript abundance among pre-IVIG and post-IVIG patients and febrile control patients. Then we analyzed the mRNA levels and the protein levels among the different cohort of patients with KD who were either responsive or nonresponsive to the initial IVIG.
RESULTS: A total of 298 transcripts were overrepresented or underrepresented in the pre-IVIG patients compared with post-IVIG patients and febrile controls, of which 15 transcripts were differentially expressed in nonresponsive patients with KD compared with responsive patients before IVIG. The protein levels of polycythemia rubra vera 1, which was one of the most variably expressed transcripts in pre-IVIG patients, and the serum granulocyte colony-stimulating factor levels were significantly higher in nonresponsive patients than in responsive patients before the initial IVIG administration.
CONCLUSION: These findings suggest that the variable gene expression profiles were correlated to the responses of patients with KD to IVIG administration. Polycythemia rubra vera 1 and granulocyte colony-stimulating factor levels may be good biomarkers for predicting response to IVIG in patients with KD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18930517     DOI: 10.1016/j.jaci.2008.09.011

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  22 in total

1.  Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients.

Authors:  Akira Hachiya; Norimoto Kobayashi; Satoshi Matsuzaki; Yusuke Takeuchi; Yohei Akazawa; Tomonari Shigemura; Noriko Motoki; Junya Masumoto; Kazunaga Agematsu
Journal:  Clin Rheumatol       Date:  2018-01-04       Impact factor: 2.980

Review 2.  Intravenous immunoglobulin therapy in rheumatic diseases.

Authors:  Jagadeesh Bayry; Vir Singh Negi; Srini V Kaveri
Journal:  Nat Rev Rheumatol       Date:  2011-05-10       Impact factor: 20.543

3.  Markedly elevated CD64 expression on neutrophils and monocytes as a biomarker for diagnosis and therapy assessment in Kawasaki disease.

Authors:  Sho Hokibara; Norimoto Kobayashi; Keiko Kobayashi; Tomonari Shigemura; Haruo Nagumo; Masahiro Takizawa; Takashi Yamazaki; Kazunaga Agematsu
Journal:  Inflamm Res       Date:  2016-03-28       Impact factor: 4.575

4.  Differentially expressed genes, lncRNAs, and competing endogenous RNAs in Kawasaki disease.

Authors:  Changsheng Guo; Yuanqing Hua; Zuanhao Qian
Journal:  PeerJ       Date:  2021-05-12       Impact factor: 2.984

5.  Increased Risk of Kawasaki Disease in Infants Born of Mothers With Immune Disorders.

Authors:  Hsiao-Wen Chu; Chien-Heng Lin; Ming-Chih Lin; Ya-Chi Hsu
Journal:  Front Pediatr       Date:  2021-05-14       Impact factor: 3.418

6.  Identification of 4-Trimethylaminobutyraldehyde Dehydrogenase (TMABA-DH) as a Candidate Serum Autoantibody Target for Kawasaki Disease.

Authors:  Atsuko Matsunaga; Yutaka Harita; Yoshio Shibagaki; Nobutaka Shimizu; Kazuhiko Shibuya; Hiroshi Ono; Hitoshi Kato; Takashi Sekine; Naoko Sakamoto; Takashi Igarashi; Seisuke Hattori
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

7.  Combined Single Nucleotide Variants of ORAI1 and BLK in a Child with Refractory Kawasaki Disease.

Authors:  Saki Kanda; Yoshimitsu Fujii; Shin-Ichiro Hori; Taichi Ohmachi; Ken Yoshimura; Koichiro Higasa; Kazunari Kaneko
Journal:  Children (Basel)       Date:  2021-05-21

8.  Integrins α4 and αM, collagen1A1, and matrix metalloproteinase 7 are upregulated in acute Kawasaki disease vasculopathy.

Authors:  Rebecca Reindel; Susan C Baker; Kwang-Youn Kim; Carol A Rowley; Stanford T Shulman; Jan M Orenstein; Elizabeth J Perlman; Mark W Lingen; Anne H Rowley
Journal:  Pediatr Res       Date:  2012-12-07       Impact factor: 3.756

9.  Increased risk of atopic dermatitis in preschool children with kawasaki disease: a population-based study in taiwan.

Authors:  Peng Yeong Woon; Wei Chiao Chang; Chi-Cheng Liang; Chun Hung Hsu; Sukhontip Klahan; Ying-Hsien Huang; Wei-Pin Chang; Ho-Chang Kuo
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-27       Impact factor: 2.629

10.  Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G.

Authors:  Shohei Ogata; Chisato Shimizu; Alessandra Franco; Ranim Touma; John T Kanegaye; Biswa P Choudhury; Natasha N Naidu; Yutaka Kanda; Long T Hoang; Martin L Hibberd; Adriana H Tremoulet; Ajit Varki; Jane C Burns
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.